180 related articles for article (PubMed ID: 38558804)
1. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy.
Zeng Y; Huang J; Pang J; Pan S; Wu Y; Jie Y; Li X; Chong Y
Front Immunol; 2024; 15():1330644. PubMed ID: 38558804
[TBL] [Abstract][Full Text] [Related]
2. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy.
Pan S; Yu Y; Wang S; Tu B; Shen Y; Qiu Q; Liu X; Su N; Zuo Y; Luan J; Zhang JY; Shi M; Meng F; Wang FS
Front Immunol; 2022; 13():892618. PubMed ID: 35711409
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
4. The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients.
Tseng CW; Liu WC; Ko PH; Chen YC; Tseng KC; Chang TT
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016434
[TBL] [Abstract][Full Text] [Related]
5. [Analysis and significance of HBV DNA below the lower detection limit of HBV RNA levels after long-term NAs antiviral therapy in patients with hepatitis B virus cirrhosis].
Wang CY; Cao Y; Feng YM; Li J; Jiang B; Zhang Y; Wen J; Zhu YJ; Li J
Zhonghua Gan Zang Bing Za Zhi; 2022 Jul; 30(7):758-762. PubMed ID: 36038347
[No Abstract] [Full Text] [Related]
6. Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era.
Wang R; Tan G; Lei D; Li Y; Gong J; Tang Y; Pang H; Luo H; Qin B
J Cancer Res Clin Oncol; 2024 Mar; 150(3):158. PubMed ID: 38530426
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.
Gane E; Verdon DJ; Brooks AE; Gaggar A; Nguyen AH; Subramanian GM; Schwabe C; Dunbar PR
J Hepatol; 2019 Nov; 71(5):900-907. PubMed ID: 31306680
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
[TBL] [Abstract][Full Text] [Related]
9. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
Zheng Z; Liao W; Liu L; Cai S; Zhu H; Yin S
Biomed Pharmacother; 2020 Feb; 122():109698. PubMed ID: 31918272
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B Reactivation in Patients Treated with Direct-Acting Antivirals for Hepatitis C.
Toka B; Köksal AŞ; Dertli R; Şirin G; Fidan S; Ülger Y; Harmandar F; Yıldırım AE; Eminler AT; Asil M; Kayar Y; Bıyık M; Kuran S; Uslan MI; Hülagü S
Dig Dis; 2022; 40(5):635-643. PubMed ID: 35108715
[TBL] [Abstract][Full Text] [Related]
11. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
12. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
[TBL] [Abstract][Full Text] [Related]
14. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
[TBL] [Abstract][Full Text] [Related]
15. Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection.
Sun F; Li Z; Hu L; Deng W; Jiang T; Wang S; Bi X; Lu H; Yang L; Lin Y; Zeng Z; Shen G; Liu R; Chang M; Wu S; Gao Y; Hao H; Xu M; Chen X; Zhang L; Lu Y; Dong J; Xie Y; Li M
Front Immunol; 2022; 13():1082091. PubMed ID: 36505492
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus.
Lin Z; Zhang X; Zhou Y; Chen C; He LN; Li H; Wang Y; Chen T; Hong S; Zhang L
Cancer Immunol Immunother; 2022 May; 71(5):1247-1255. PubMed ID: 34647153
[TBL] [Abstract][Full Text] [Related]
17. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion.
Papatheodoridis GV; Lekakis V; Voulgaris T; Lampertico P; Berg T; Chan HLY; Kao JH; Terrault N; Lok AS; Reddy KR
J Hepatol; 2022 Dec; 77(6):1670-1689. PubMed ID: 35850281
[TBL] [Abstract][Full Text] [Related]
19. Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
Wang Y; Liao H; Deng Z; Liu Y; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Duan Z; Lu F; Zheng S
J Viral Hepat; 2022 Jun; 29(6):420-431. PubMed ID: 35274400
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]